Suppr超能文献

新型喹诺酮类抗菌药物与含锰诊断药物之间的相互作用。

Interactions between new quinolone antibacterials and diagnostic drug containing manganese.

作者信息

Hosono Moeko, Yokoyama Haruko, Takayanagi Risa, Yamada Yasuhiko

机构信息

Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan.

出版信息

Eur J Drug Metab Pharmacokinet. 2013 Dec;38(4):255-9. doi: 10.1007/s13318-013-0120-6. Epub 2013 Feb 27.

Abstract

A diagnostic drug containing manganese chloride tetrahydrate as a major ingredient is available since 2006. It is used in magnetic resonance imaging as a negative contrast medium for magnetic resonance cholangiopancreatography of the gastrointestinal tract. However, there is no report regarding interaction between manganese and new quinolone antibacterials. We investigated the interactions between new quinolone antibacterials and a diagnostic drug containing manganese in vitro. We evaluated the rate of formation of chelate complex by reacting new quinolone antibacterials (levofloxacin, ofloxacin, ciprofloxacin) with a diagnostic drug containing manganese. The EC50 values of the formation of chelate complex for levofloxacin, ofloxacin, and ciprofloxacin were 5.14 ± 0.14, 5.29 ± 0.14, and 0.96 ± 0.04 mM, respectively. The rates of formation of chelate complex by levofloxacin, ofloxacin, and ciprofloxacin in a reaction with the diagnostic drug were 17.0, 18.9, and 55.5 % in clinical condition, respectively. Our results suggest that a complex of each antibacterial and manganese was formed, with ciprofloxacin causing the strongest interaction. In addition, our findings indicate that the degree of interaction may be an important problem in clinical settings with concomitant administration of a new quinolone antibacterial and diagnostic drug containing manganese.

摘要

一种以四水合氯化锰为主要成分的诊断药物自2006年起就已存在。它在磁共振成像中用作胃肠道磁共振胰胆管造影的阴性对比剂。然而,尚无关于锰与新型喹诺酮类抗菌药物之间相互作用的报道。我们在体外研究了新型喹诺酮类抗菌药物与含锰诊断药物之间的相互作用。我们通过使新型喹诺酮类抗菌药物(左氧氟沙星、氧氟沙星、环丙沙星)与含锰诊断药物反应来评估螯合复合物的形成速率。左氧氟沙星、氧氟沙星和环丙沙星形成螯合复合物的EC50值分别为5.14±0.14、5.29±0.14和0.96±0.04 mM。在临床条件下,左氧氟沙星、氧氟沙星和环丙沙星与诊断药物反应形成螯合复合物的速率分别为17.0%、18.9%和55.5%。我们的结果表明,每种抗菌药物与锰形成了复合物,其中环丙沙星的相互作用最强。此外,我们的研究结果表明,在同时使用新型喹诺酮类抗菌药物和含锰诊断药物的临床环境中,相互作用的程度可能是一个重要问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验